Radiation pneumonitis (RP) is one of the most common dose-limiting toxicities in thoracic X-ray radiotherapy (XRT). Dosimetric factors are used for prediction of the occurrence of RP after XRT. Carbon-ion radiotherapy (CRT) is a promising modality because of its excellent dose localization and high biological effect on tumors. This study aims to analyze the relationship between dosimetric factors developed for XRT and the incidence of RP in patients with stage I non-small cell lung cancer (NSCLC) after CRT. We examined 80 inoperable patients with NSCLC. The ranges of the daily fraction sizes and the total doses were from 3.3 to 8.8 GyE and from 59.4 to 95.4 GyE, respectively. These doses were successfully delivered with acceptable toxicity; grade 2 RP was observed in 8 patients (10%). The severity of RP was graded within 6 months of the initiation of CRT using the Radiation Therapy Oncology Group criteria. These results indicate the excellent dose distribution of CRT. We then compared the dosimetric data of the 8 patients developed grade 2 RP with those of 72 patients developed grade 1 RP. Dosimetric factors useful for predicting RP in XRT, such as the percentage of the computed tomography-defined total lung volume receiving > 5, > 20, and > 30 GyE, and mean lung dose, were not predictive factors for RP after CRT. The dosimetric factors used for XRT are not applicable for CRT in patients with NSCLC. The dosimetric factors for CRT remain to be developed.
delivering homogeneous radiation doses to an irregular three-dimensional volume by making use of the physical characteristics of the Bragg peak. As a result, the dose delivered to the normal tissue surrounding the tumor can be reduced more effectively than with XRT. It is legitimate to conclude that carbon-ion radiotherapy (CRT) can achieve complete control of the lung tumor without any increase in the risk of developing RP as compared with XRT.
Since November 1994, a phase I/II doseescalation study on CRT has been performed for clinical stage I NSCLC. This paper presents the results of our analysis regarding the significance of dosimetric factors in the development of RP associated with CRT for stage I NSCLC.
MATERIALS AND METHODS

Patient population
From November 1994 to February 1999, 81 patients with clinical stage I NSCLC were treated in phase I/II studies using carbon ions at NIRS (Miyamoto et al. 2003) . One patient who was simultaneously treated for 2 lung lesions was excluded from this analysis. The total number of patients included in the analysis was therefore 80. Patient and tumor characteristics are shown in Table  1 . All the tumors were located in the peripheral regions of the lungs. All patients had given informed consent to the clinical trial.
Treatment procedures
The patients included in the current analysis were treated in 2 dose-escalation studies for CRT. Doseescalation was performed using a fixed fraction number and a predetermined overall treatment time. In order to express carbon ion doses in terms comparable to megavoltage X-ray beams, the Gray-equivalent dose (GyE) was defined as the physical carbon dose multiplied by the relative biological effectiveness ). In the first protocol (protocol 9303), the patients were treated with 18 fractions over 6 weeks. The patients were initially treated with a total dose of 59.4 GyE at a fraction size of 3.3 GyE. The doses were then increased in 5-10% increments for every 3 to 5 patients based on the careful observation of normal tissue responses and eventually maintained at 95.4 GyE. Of the 80 patients, 46 were registered for this protocol. The remaining 34 patients were enrolled in the second protocol (protocol (NSCLC) is commonly observed among patients with an extensive smoking history; these patients also suffer from other smoking-related diseases such as coronary disease and chronic obstructive pulmonary disease (COPD). Accordingly, a section of the patients are diagnosed as medically inoperable and referred for X-ray radiotherapy (XRT); however, local tumor control with XRT is generally inferior to that obtained by surgical resection. There is substantial evidence that local control probabilities have been improved as the prescribed dose of XRT increases (Hayman et al. 2001) . However, in the treatment of lung cancer, the risk of developing radiation pneumonitis (RP) has limited any attempts for dose escalation that might improve local control probabilities (Hazuka et al. 1993) .
The advent of three-dimensional planning systems has allowed for the collection of detailed information regarding the dose-volume distribution in structures of interest. There are several reports dealing with the relationship between the dosimetric data and radiation-induced toxicities in a variety of organs, such as the lung, liver, and esophagus (Graham et al. 1999; Takeda et al. 2006; Kim et al. 2007 ). It has been reported that dosimetric factors, such as mean lung dose (MLD), the percentage of CT-defined total lung volume receiving > 20 Gy (V20) and > 30 Gy (V30), and normal tissue complication probability (NTCP) are strongly related to the development of RP (Armstrong et al. 1995; Kwa et al. 1998; Graham et al. 1999; Hernando et al. 2001) .
In June 1994, clinical trials with carbon ions generated from a dedicated medical accelerator, the Heavy Ion Medical Accelerator in Chiba (HIMAC), were initiated at the National Institute of Radiological Sciences (NIRS), Chiba, Japan (Tsujii et al. 1997 ). The carbon ions produce an increased density of local energy deposition with high linear energy transfer (LET) components, resulting in increased biological effects (Kanai et al. 1997 . Accordingly, carbon ion RT is assumed to be effective against hypoxic or slowgrowing tumors that are considered to be resistant to low LET radiation including photons and protons. In addition, carbon ions can be shaped for 9701) that used 9 fractions over 3 weeks with dose escalation from 68.4 GyE to 79.2 GyE in increments of 5%. No attempt was made to cover the lymphatic lesions in loci such as the hilum and mediastinum.
Carbon ion irradiation technique
The patients were first immobilized in the supine or prone position with custom-made devices consisting of a semi-cylindrically shaped rotary capsule. Chest CT scans were performed at 5-mm intervals to obtain 5-mmthick slices. CT planning was performed using a threedimensional planning system, the HIPLAN (Endo et al. 1996) .
In treatment planning, the gross tumor volume (GTV) was defined as the visible extent of the tumor on the CT image at the lung window. The clinical target volume (CTV) was determined by allowing for a 5-mm margin beyond the GTV. The internal target volume (ITV) was designated by adding the internal margin (IM) to the CTV corresponding to the tumor movement. The ITV was reduced with the introduction of the respiratorygated irradiation system (Minohara et al. 2000) . The treatment position of the patient was fluoroscopically confirmed and the set-up error, if any, was corrected in the 3 perpendicular directions during each treatment session. The planning target volume (PTV) can, therefore, be considered equal to the ITV such that ITV = CTV + IM. The distal and proximal margins of the PTV from the beam direction were defined as the 3-mm waterequivalent path length, and the aperture margin was set at 3 mm.
The carbon-ion irradiation techniques employed were the right-angled field method in 26 patients, the parallel-opposed field method in 3 patients, the 3-field method in 3 patients, and the 4-field method without parallel-opposed directions in 48 patients. All the patients were irradiated using 1 field a day. The initial 18 patients in the 9303 protocol were irradiated without respiratorygating, and the subsequent 62 patients were treated using respiratory-gated irradiation. The representative dose distribution is shown in Fig. 1 .
Dosimetric factors
Bilateral lung volume was contoured and defined to exclude the GTV. The following dosimetric factors were extracted from both the bilateral and ipsilateral lung dose-volume histograms: the V5, V20, V30, and MLD for bilateral lungs and the V5(i), V20(i), V30(i) and MLD(i) for an ipsilateral lung. The V5, V20, and V30 were defined as the percentages of the CT-defined total lung volume receiving 5 GyE, 20 GyE, and 30 GyE. The MLD was calculated as the average dose administered to the CT-defined lung (Hernando et al. 2001) . It has been reported that V20, V30, and MLD from the dose-volume histograms of bilateral lungs are predictive factors for the development of RP in XRT for lung cancer.
Evaluation of RP
After treatment, the patients, including both outpatients and inpatients, were followed up monthly for regular examination with chest X-rays and CT. Diagnosis of RP was based on clinical symptoms including cough, shortness of breath, fever, and radiographic findings that were confirmed by more than 2 radiation oncologists. The severity of RP within 6 months of the initiation of CRT was graded using the Radiation Therapy Oncology Group (RTOG) acute lung morbidity scoring criteria (Cox et al. 1995) . In this study, the criteria for assessing the symptoms occurring within 90 days from the commencement of radiotherapy were extended to a total observation time of up to 6 months.
A student's t-test was used to evaluate the relationship between the dosimetric factors and grade 2 RP. Statistical analysis was performed with SPSS version 11.
RESULTS
All the patients completed the treatment. Of the 80 patients, 10 patients developed RP: 2 patients developed grade 1; 5, grade 2; and 3, grade 3. The time until the onset of symptoms was 9 to 14 weeks (median: 10 weeks) from the time of initiation of CRT. Seventy patients were scored as grade 0. No patient developed grade 4 or higher RP.
In the low-dose groups of the 9303 protocol, 2 patients with parallel-opposed field irradiation developed grade 3 RP. However, following the use of the 4-field and respiratory-gated irradiation systems, dose escalation was performed safely up to the dose level of 95.4 GyE. In the 9701 protocol, only 1 patient developed grade 3 RP. Grade 2 RP was discovered in 2 of 5 patients treated with a total dose of 79.2 GyE. At this dose level, the dose-escalation study was terminated (Table 2) .
Three patients developed grade 3 RP at 9 to 13 weeks after the beginning of CRT. They exhibited symptoms of cough, shortness of breath, and high fever and were subsequently treated with steroids. The clinical symptoms improved temporarily, but the exacerbation of RP occurred in 2 patients at 7 months. However, the RP condition ultimately improved in all of these 3 patients. All the patients were kept under observation for more than a year. Late lung toxicity at 1 year from the commencement of CRT was within the acceptable range for all the 10 patients concerned.
To prevent RP, the recommended V20 or V30 was established at 25% (Graham et al. 1999) or 18% (Hernando et al. 2001 ), respectively; these values were fallen short of for all subjects. The mean values for the dosimetric factors in the grade 0 and 1 and the grade 2 and 3 groups, as well as the p values from the t-test, are shown in Table 3 . None of the dosimetric factors, including the V5, V20, V30, and MLD, are significantly correlated with the incidence of grade 2 RP. In the dose-volume histogram analysis using an ipsilateral lung, dosimetric factors, including V5(i), V20(i), V30(i), and MLD(i), were also not predictive factors for the RP occurrence (Table 4) .
DISCUSSION
It has been reported that a correlation exists between dosimetric factors, such as V20 (Graham et al. 1999) , V25 (Armstrong et al. 1995) , V30 (Hernando et al. 2001) , MLD (Kwa et al. 1998; Graham et al. 1999; Hernando et al. 2001) , or NTCP (Armstrong et al. 1995; Graham et al. 1999) , and the incidence of RP ( grade 2 or grade 3) in XRT for lung cancer. Graham et al. (1999) showed that 25% of the V20 was the cutoff value between the low and intermediate risk in the development of RP. Hernando et al. (2001) found that the pulmonary morbidity was significantly lower when the V30 was less than 18%. It has also been reported that the development of RP was less than 10% if the MLD was less than 10 Gy (Kwa et al. 1998; Graham et al. 1999; Hernando et al. 2001) . However, these studies included patients with diseases of stage II or higher that needed nodal area irradiation. Conventional radiotherapy using 2 Gy was mostly performed in these studies; however, in our CRT study, the daily fraction varied from 3.3 GyE to 8.8 GyE. Although all the dosimetric data in CRT for stage I NSCLC were less than 25% for V20 and 18% for V30 and the MLD was also less than 10 GyE, it may not be appropriate to directly compare the dosimetric data of conventional radiation with our data. Fujino et al. (2006) analyzed the risk factor of RP after hypofractionated stereotactic radiotherapy for 156 patients with stage I NSCLC. They concluded that the V20, total dose and the dose per fraction were not predictive of RP. Recently, Wang et al. (2006) reported V5, which is the most irradiated volume, to be the only independent dosimetric factor in predicting the occurrence of RP in esophageal cancer patients treated with concurrent chemoradiation plus surgery. However, V5 was not a predictive factor for the occurrence of RP in the clinical study.
The severity of RP within 6 months after the commencement of CRT was graded in this study. RP typically occurs within 6 months from the beginning of the treatment in XRT (Cox et al. 1990; Maasilta 1991) . Further, Hernando et al. (2001) defined that RP with clinical symptoms appeared within 6 months of XRT according to the criteria in their study. Graham et al. (1999) defined RP as that which occurred early or late according to the RTOG/European Organization for Research and Treatment of Cancer (EORTC) criteria. We reported that late pulmonary morbidities after CRT were milder than acute pulmonary morbidities. Late lung morbidities were scored as Grade 1 in 78 patients and Grade 2 in 1 patient using the RTOG/EORTC late radiation morbidity scoring (Miyamoto et al. 2003) . Therefore, our definition of RP appeared reasonable. We classified acute lung damage based on CT density in our previous report (Nishimura et al. 2003) . All the radiographic pulmonary changes occurred in the irradiated volume. The scoring of the damage was significantly associated with the dosimetric factors; however, it did not correspond to the scoring of the acute clinical symptoms.
In XRT for stage I NSCLC with a total dose of 60-70 Gy using conventional fractionation or hyperfractionation, the incidence of grade 3 RP is less than 10% (Jeremic et al. 1997; Sibley 1998) . In our CRT, the ranges of the daily fraction sizes and the total doses were from 3.3 GyE to 8.8 GyE and from 59.4 GyE to 95.4 GyE, respectively. These doses were successfully delivered with acceptable toxicity, and grade 3 RP was observed in only 3.75% (3/80) of the patients. It was anticipated that the lung reactions to carbon ions administered as high LET beams would be more severe as compared to that with low LET radiation. However, the clinical lung toxicity in CRT was rather mild. The lungs are classified as parallel structures, and a main parameter for pulmonary function impairment is the proportion of the organ that has received a dose above the tolerance level. Therefore, the dose distribution is more important than the biological characteristics for lung toxicity in terms of clinical symptoms in CRT.
Most reports about lung dosimetric factors are using dosimetric data of bilateral lungs because lungs are classified as parallel organs in XRT. In this study, dosimetric data of an ipsilateral lung were analyzed for the occurrence of RP, since the biological characteristics of carbon ions were not similar to those of X-ray. However, dosimetric factors of an ipsilateral lung were also not predictive factors of the occurrence of RP.
We have reported the administration of the maximum dose in this study, the use of parallelopposed fields, and respiratory-gated irradiation may be predictive factors for the development of grade 2 RP in CRT (Miyamoto et al. 2003) . However, all these factors were related to the dosimetric factors; further, they were all acceptable in this study. Total tumor control was achieved at the maximum doses in each protocol, namely, 95.4 GyE in 18 fractions and 79.2 GyE in 9 fractions, respectively. It has been suggested that the use of parallel-opposed fields increases the risk of RP. The 2 patients who were irradiated from parallel-opposed fields and developed grade 3 RP belonged to the low-dose groups; from the evidence of the dosimetric data, we have not been able to identify the differences between these 2 patients and the patients without RP. At present, we have not applied this field plan for stage I NSCLC treatment. Respiratory-gated irradiation plays an extremely important role in reducing the amount of unnecessary irradiation to healthy lung tissue. We have found that the PTV could be reduced by an average of 29.5% by using the respiratory-gated irradiation system in CRT for lung tumors and hepatomas (Osaka et al. 1999 ). Moreover, respiratory-gated irradiation reduces the uncertainty over the pass length of carbon ions due to respiratory motion. Clinical data such as age, gender, pulmonary function, and COPD were not significant factors influencing the development of RP (Miyamoto et al. 2003) .
In summary, in this study, CRT was successfully performed in all the inoperable patients with stage I NSCLC, with 8 patients developing grade 2 RP. The results of these clinical studies have demonstrated that the dosimetric factors cannot be relied upon as predictors for progression to grade 2 RP in high dose CRT for stage I NSCLC. However, the number of the patients in this study might be not enough to detect the relationship between the dosimetric factors and the RP occurrence after CRT. Further studies will be necessary.
